Pharmaxis Ltd’s publication on Journal of Cellular and Molecular Medicine.
SMC announced that Pharmaxis Ltd has published the results of a study using STAM™ model on Journal of Cellular and Molecular Medicine.
Title: “The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis”
Read more….https://www.ncbi.nlm.nih.gov/pubmed/30536539